Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Phosphorus attached directly or indirectly to the diazine ring by nonionic bonding

Subclass of:

544 - Organic compounds -- part of the class 532-570 series

544000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

544000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

544001000 - Hetero ring is six-membered having two or more ring hetero atoms of which at least one is nitrogen (e.g., selenazines, etc.)

544224000 - The six-membered hetero ring consists of two nitrogens and four carbons (e.g., 1,2-diazines, etc.)

544242000 - 1,3-diazines

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
544243000 Phosphorus attached directly or indirectly to the diazine ring by nonionic bonding 30
20110172423CYCLIC PHOSPHAZENE COMPOUNDS AND USE THEREOF IN ORGANIC LIGHT EMITTING DIODES - An organic light-emitting diode comprising at least one cyclic phosphazene compound, a light-emitting layer formed from at least one matrix material and at least one emitter material, wherein the at least one matrix material comprises at least one cyclic phosphazene compound, the use of cyclic phosphazene compounds in organic light-emitting diodes and a device selected from the group consisting of stationary visual display units, mobile visual display units and illumination units comprising at least one inventive organic light-emitting diode, and selected cyclic phosphazene compounds and processes for preparing them.07-14-2011
20120010406COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.01-12-2012
20120010407COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.01-12-2012
20140073786CYCLOHEXENYL NUCLEIC ACIDS ANALOGS - The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclohexenyl nucleic acid analogs are provided, having one or more chiral substituents, that are expected to be useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.03-13-2014
544244000 Polycyclo ring system having the diazine ring as one of the cyclos 26
20090012292NOVEL PROCESS FOR ACYCLIC PHOSPHONATE NUCLEOTIDE ANALOGS - The present invention provides a novel process for the preparation of acyclic phosphonate nucleotide analogs using novel intermediates. Thus, for example, (R)-9-(2-phosphonomethoxypropyl)adenine is reacted with dimethylformamide dimethylacetal to give N01-08-2009
20090149648NUCLEOTIDE ANALOGS - Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.06-11-2009
20090187019Process for preparing diisopropyl((1-(hydroxymethyl)-cyclopropyl)oxy)methylphosphonate - The present invention relates to a new process for preparing diisopropyl {[1-(hydroxymethyl)-cyclopropyl]oxy}methylphosphonate (2), which is a key intermediate for synthesizing an antiviral (particularly, against hepatitis B virus) nucleoside analogue. The present invention also relates to new intermediates, and a process for preparing the antiviral nucleoside analogue from the compound (2) prepared according to the present invention.07-23-2009
20090270618PHOSPHONYL ESTER CONJUGATES AS PRODRUGS - Cidofovir or foscarnet based compounds having an amino acid or dipeptide esters are provided as prodrugs.10-29-2009
20090286981PROCESS FOR THE PREPARTION OF TENOFOVIR - The present invention relates to novel Tenofovir disoproxil hemifumarate salt, which is prepared by dealkylation of Phosphonate esters by using mineral acids followed by esterification and crystallization to give crystalline Tenofovir disoproxil. The Tenofovir disoproxil is further converted to fumarate salts with improved yield.11-19-2009
20100099869NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS - This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R04-22-2010
20100292470ADEFOVIR DIPIVOXIL CRYSTALLINE MONOHYDRATE FORM - Adefovir Dipivoxil monohydrate crystalline is disclosed.11-18-2010
20110112292Crystalline Form of Tenofovir Disoproxil and a Process for Its Preparation - Crystalline Form C of tenofovir disoproxil, salts thereof and a process for its preparation. The process involves adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water, whereby the crystalline Form C of tenofovir disoproxil precipitates. The crystalline Form C of tenofovir disoproxil may be converted to a salt thereof. There is also provided a process for purifying a crude product comprising tenofovir monoisoproxil and tenofovir disoproxil.05-12-2011
20110207928PURIFICATION METHOD FOR ADEFOVIR DIPIVOXIL - The present invention relates to a novel method of purifying adefovir dipivoxil of Formula 1. The purification method according to the present invention comprises the steps of dissolving impure adefovir dipivoxil containing byproducts generated during a synthetic reaction, salts thereof or complexes thereof in water or a water-containing mixed solvent; purifying the adefovir dipivoxil solution through a reverse-phase column; and adding a base to the purified adefovir dipivoxil solution and extracting the same with an organic solvent.08-25-2011
20110207929Process for preparing aminocrotonylamino-substituted quinazoline derivatives - The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I)08-25-2011
20110207930IMPROVED PRODUCTION METHOD FOR ADEFOVIR DIPIVOXIL - The present invention relates to an improved method of preparing adefovir dipivoxil of Formula 1. The method of the present invention is characterized by using dimethylsulfoxide as a reaction solvent, and comprises a process of preparing adefovir dipivoxil of Formula 1 by allowing adefovir of Formula 2 to react with chloromethylpivalate at a reaction temperature of 30 to 50° C. under the presence of dimethylsulfoxide and triethylamine solvents.08-25-2011
20120035362PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID - The present invention provides for compounds of Formula I:02-09-2012
20120077978Structure Based Design Of Inhibitors Of Human Thymidylate Synthase - A compound is provided having the chemical structure:03-29-2012
20120101273NOVEL CRYSTAL FORMS OF ADEFOVIR DIPIVOXIL AND PROCESSES FOR PREPARING THE SAME - The present invention relates to novel Forms A, B, C, D, E, F and G of crystalline 9-[2-[phosphonomethoxy]ethyl]adenine bis-pivaloyloxymethyl ester, i.e., adefovir dipivoxil, and processes for preparing them. According to the present invention, said novel crystal forms having a high purity can be obtained by a simple method and in a high yield.04-26-2012
20120238753PROCESS FOR THE PREPARATION OF ADEFOVIR DIPIVOXIL - An improved process for the preparation of adefovir dipivoxil and its pharmaceutically acceptable salts or solvates comprises the condensation of adefovir with chloro methyl pivalate in a mixture of two or more solvents in the presence of a base and isolating the resulting adefovir dipivoxil.09-20-2012
20130005969PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE - The present invention relates to an improved process for the preparation of Tenofovir Disoproxil and its pharmaceutically acceptable salts comprising the steps of: a) esterifying Tenofovir with chloromethyl isopropyl carbonate in presence of a base, phase transfer catalyst and optionally dehydrating agent, in a suitable solvent; b) optionally purifying Tenofovir Disoproxil; and c) converting of Tenofovir Disoproxil into its pharmaceutically acceptable salts. The present invention further relates to a process for the preparation of Tenofovir by reacting 1-(6-amino-purin-9-yl)-propan-2-ol with toluene-4-sulfonic acid diethoxy phosphoryl methyl ester in presence of a base in a non-polar solvent medium followed by hydrolysis.01-03-2013
20130090473Methods for preparing anti-viral nucleotide analogs - Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16):04-11-2013
20140128602METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS - Methods for isolating 9-{(R)-2-[((S)—{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16):05-08-2014
20140187773TENOFOVIR ALAFENAMIDE HEMIFUMARATE - A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).07-03-2014
20140275532ACYCLIC NUCLEOSIDE PHOSPHONATE DIESTERS - The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.09-18-2014
20140303367Methods for Synthesizing Molybdopterin Precursor Z Derivatives - Provided herein are synthetic methods for preparing a compound of formula (I):10-09-2014
20140303368PROCESS FOR THE PREPARATION OF TENOFOVIR - The present invention provides a process for preparation of tenofovir by dealkylation of its phosphonate ester using Ionic complexes. The present invention also provides a process for preparation of tenofovir disoproxil or a salt thereof using the tenofovir of the present invention.10-09-2014
20140323726Methods for synthesizing molybdopterin precursor Z derivatives - Provided herein are synthetic methods for preparing a compound of formula (I): Also provided herein are synthetic methods for preparing a compound of formula (XIII): The disclosure also provides useful intermediates, derivatives, prodrugs, and pharmaceutically acceptable salts, solvates and hydrates of the formula (I) and formula (XIII) compounds. These compounds are useful for treating diseases associated with molybdenum cofactor deficiency.10-30-2014
20150291638METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS - Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16):10-15-2015
20160122373AN EFFICIENT PROCESS FOR SEPARATION OF DIASTEREOMERS OF 9-[(R)-2-[[(R,S)-[[(S)-1-(ISOPROPOXYCARBONYL)ETHYL]AMINO]-PHENOXYPHOSPHIN- YL] METHOXY]PROPYL]ADENINE - The present invention relates to an efficient process for the separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine and to a process for preparing 9-[(R)-2-[[(R)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine and 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine.05-05-2016
20170233420HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE08-17-2017

Patent applications in all subclasses Phosphorus attached directly or indirectly to the diazine ring by nonionic bonding

Website © 2023 Advameg, Inc.